Literature DB >> 16636092

Dynamic hyperinflation: is it worth measuring?

Peter M A Calverley1.   

Abstract

A reduced exercise capacity is an important determinant of health status and an independent prognostic marker in patients with chronic obstructive pulmonary disease. The inability to increase expiratory flow at the resting end-expiratory lung volume in the face of expiratory-flow limitation means that end-expiratory lung volume must increase if gas exchange is to be maintained near normal values. This phenomenon is usually referred to as dynamic hyperinflation. The change in operating lung volumes during exercise is related to the intensity of breathlessness. Treatments such as bronchodilators that increase inspiratory capacity or supplemental oxygen, which reduces ventilatory demand, decrease the degree of dynamic hyperinflation at any external workload. However, dynamic hyperinflation is not seen universally in patients with chronic obstructive pulmonary disease as some adopt different breathing patterns when they exercise, or respond to inhaled bronchodilators by changing their pattern of abdominal muscle activation, a behavior that can be counterproductive. Finally, dynamic hyperinflation can be reduced when, for example, breathing oxygen after exercise without changes in dyspnea, as other factors are more important determinants of this symptom in these circumstances. Dynamic hyperinflation can be reliably measured from the inspiratory capacity maneuver in many laboratories. Although knowledge about this variable gives great insight into the mechanisms of therapy, its routine measurement cannot currently be recommended as it does not appear to add additional clinical data beyond those available in present laboratory exercise testing protocols.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636092     DOI: 10.1513/pats.200508-084SF

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  8 in total

1.  Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?

Authors:  Koichi Nishimura; Maya Yasui; Takashi Nishimura; Toru Oga
Journal:  Respir Res       Date:  2011-10-11

Review 2.  Optoelectronic Plethysmography has Improved our Knowledge of Respiratory Physiology and Pathophysiology.

Authors:  Isabella Romagnoli; Barbara Lanini; Barbara Binazzi; Roberto Bianchi; Claudia Coli; Loredana Stendardi; Francesco Gigliotti; Giorgio Scano
Journal:  Sensors (Basel)       Date:  2008-12-05       Impact factor: 3.576

3.  Does impaired O2 delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD-CHF?

Authors:  Mayron F Oliveira; Joel T J Zelt; Joshua H Jones; Daniel M Hirai; Denis E O'Donnell; Samuel Verges; J Alberto Neder
Journal:  Front Physiol       Date:  2015-01-07       Impact factor: 4.566

4.  Exercise performance and differences in physiological response to pulmonary rehabilitation in severe chronic obstructive pulmonary disease with hyperinflation.

Authors:  André Luis Pereira de Albuquerque; Marco Quaranta; Biswajit Chakrabarti; Andrea Aliverti; Peter M Calverley
Journal:  J Bras Pneumol       Date:  2016-04       Impact factor: 2.624

Review 5.  Exercise dyspnea in patients with COPD.

Authors:  Loredana Stendardi; Barbara Binazzi; Giorgio Scano
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 6.  Role of tiotropium in the treatment of COPD.

Authors:  Kathryn L Rice; Ken M Kunisaki; Dennis E Niewoehner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

7.  Impact of laughter on air trapping in severe chronic obstructive lung disease.

Authors:  Martin H Brutsche; Paul Grossman; Rebekka E Müller; Jan Wiegand; Florent Baty; Willibald Ruch
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

8.  Dynamics of chest wall volume regulation during constant work rate exercise in patients with chronic obstructive pulmonary disease.

Authors:  L S Takara; T M Cunha; P Barbosa; M K Rodrigues; M F Oliveira; L E Nery; J A Neder
Journal:  Braz J Med Biol Res       Date:  2012-12       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.